CytoDyn, Inc. (CYDY)

OTCMKTS: CYDY · Delayed Price · USD
0.440
+0.033 (7.98%)
Jun 24, 2022 4:00 PM - Market closed
7.98%
Market Cap 316.06M
Revenue (ttm) 266,000
Net Income (ttm) -144.76M
Shares Out 718.32M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Ex-Dividend Date n/a
Volume 908,344
Open 0.390
Previous Close 0.408
Day's Range 0.390 - 0.447
52-Week Range 0.230 - 2.540
Beta -0.60
Analysts Sell
Price Target n/a
Earnings Date n/a

About CYDY

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretrovi... [Read more...]

Industry Biotechnology
Employees 24
Stock Exchange OTCMKTS
Ticker Symbol CYDY
Full Company Profile

Analyst Forecast

No stock price forecast available yet.

Price Target
0
Analyst Consensus: Sell
Stock Forecasts

News

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the pot...

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for m...

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scie...

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for m...

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replica...

VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the po...

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

Live webcast to be held March 31 discussing announcement

CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the p...

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the company over a video that features the former CEO f...

CytoDyn CEO ousted after year of lawsuits, FDA rebuke, and ongoing investigations

Nader Pourhassan has been ousted as CEO and president by the board of directors of embattled Vancouver, Wash.

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

VANCOUVER, Wash.--(BUSINESS WIRE)--Today the Board of Directors (“the Board”) of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist...

Most Popular Penny Stocks to Buy Right Now? 3 For Your List

Can penny stocks continue to make headway in 2022? The post Most Popular Penny Stocks to Buy Right Now?

Other symbols: AUYGNUS

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn to Hold Webcast and Live Q/A on January 13

VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the pot...

Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronli...

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Regnum Corp. (OTCMKT: RGMP) ("Regnum"), CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn"), and SevenScore Pharmaceuticals, LLC ("SevenScore"), today announced the assignmen...

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill...

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn to Hold Webcast and Live Q/A on December 14

VANCOUVER, Washington, Dec. 10, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the pot...

CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Popu...

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multip...

CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn's CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim...

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clini...

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2...

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB:CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple the...

CytoDyn Announces Preliminary Results from 2021 Annual Meeting

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple th...

CytoDyn Reminds Stockholders to Register 24 hours before November 24th Annual Meeting

Management Team Will Present on Company's Strategy Going Forward

CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review

Second portion out of three major portions of BLA (CMC portion) will be submitted shortly